Gemtuzumab ozogamicin
- Generic Name
- Gemtuzumab ozogamicin
- Brand Names
- Mylotarg
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 220578-59-6
- Unique Ingredient Identifier
- 8GZG754X6M
- Background
Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheamicin per mole of antibody . The antibody ...
- Indication
Indicated for the treatment of patients with CD33 positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for other cytotoxic chemotherapy. Indicated for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial tr...
- Associated Conditions
- Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia (AML), Relapsed Acute Myelogenous Leukemia (AML)
- Associated Therapies
- -
A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia
- First Posted Date
- 2023-07-21
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT05955261
- Locations
- 🇺🇸
Rady Children's Hospital-San Diego, San Diego, California, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸Cook Children's Medical Center, Fort Worth, Texas, United States
Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients With AML
- Conditions
- Interventions
- First Posted Date
- 2022-12-23
- Last Posted Date
- 2022-12-23
- Lead Sponsor
- German Cancer Research Center
- Target Recruit Count
- 12
- Registration Number
- NCT05662904
- Locations
- 🇩🇪
University Hospital Heidelberg, Internal Medicine V, Heidelberg, Germany
🇩🇪University Hospital Dresden, Department of Medicine I, Dresden, Germany
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
- Conditions
- Interventions
- First Posted Date
- 2022-09-28
- Last Posted Date
- 2024-11-27
- Target Recruit Count
- 18
- Registration Number
- NCT05558124
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2022-01-10
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- LLS PedAL Initiative, LLC
- Target Recruit Count
- 98
- Registration Number
- NCT05183035
- Locations
- 🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Alliance for Childhood Diseases dba Cure 4 The Kids Foundation, Las Vegas, Nevada, United States
Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia
- First Posted Date
- 2021-06-07
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT04915612
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study Of Treatment Patterns And Clinical Outcomes In Patients Diagnosed With Acute Myeloid Leukemia Who Received Mylotarg in the Real-World
- Conditions
- First Posted Date
- 2020-04-07
- Last Posted Date
- 2021-08-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 32
- Registration Number
- NCT04337138
- Locations
- 🇺🇸
Pfizer Investigational Site, New York, New York, United States
AflacLL1901 (CHOA-AML)
- First Posted Date
- 2020-03-30
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Emory University
- Target Recruit Count
- 8
- Registration Number
- NCT04326439
- Locations
- 🇺🇸
Egleston Hospital, Atlanta, Georgia, United States
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Conditions
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationDrug: AsparaginaseDrug: Asparaginase Erwinia chrysanthemiProcedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyBehavioral: Cogstate Assessment BatteryProcedure: Computed TomographyDrug: CytarabineDrug: EtoposideDrug: Dexrazoxane HydrochlorideDrug: Daunorubicin HydrochlorideOther: Fludeoxyglucose F-18Drug: Gemtuzumab OzogamicinDrug: Gilteritinib FumarateDrug: Liposome-encapsulated Daunorubicin-CytarabineDrug: MethotrexateProcedure: Magnetic Resonance ImagingDrug: Mitoxantrone HydrochlorideProcedure: Positron Emission TomographyDrug: Therapeutic Hydrocortisone
- First Posted Date
- 2020-03-03
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 1400
- Registration Number
- NCT04293562
- Locations
- 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸USA Health Strada Patient Care Center, Mobile, Alabama, United States
🇺🇸Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia
- First Posted Date
- 2019-12-20
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 24
- Registration Number
- NCT04207190
- Locations
- 🇺🇸
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib
- Conditions
- Interventions
- First Posted Date
- 2019-11-22
- Last Posted Date
- 2023-03-27
- Lead Sponsor
- University Hospital Heidelberg
- Target Recruit Count
- 50
- Registration Number
- NCT04173585
- Locations
- 🇩🇪
University Hospital Heidelberg, Internal Medicine V, Heidelberg, Baden-Württemberg, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.